Pharma group Élan has reported a net loss of $60.3m in the first half of 2012.
This is an improvement on the same period last year and includes a loss incurred in disposal of a stake in Alkermes in March.
This was despite an increase of 11% in revenue to $576.4m to the end of June. This was due to a growth in demand for Tyasabri, used in the treatment of multiple sclerosis.
Élan CEO Kelly Martin said that new patients using Tysabri added to the "underlying strength in the Tysabri business".
Élan's headquarters is in Dublin and it employs 400 worldwide.
